24.39
price up icon0.72%   0.175
after-market Handel nachbörslich: 24.40 0.010 +0.04%
loading
Schlusskurs vom Vortag:
$24.21
Offen:
$24.51
24-Stunden-Volumen:
24,910
Relative Volume:
0.77
Marktkapitalisierung:
$291.95M
Einnahmen:
$9.71M
Nettoeinkommen (Verlust:
$-29.96M
KGV:
-7.0086
EPS:
-3.48
Netto-Cashflow:
$-14.79M
1W Leistung:
-2.13%
1M Leistung:
+0.29%
6M Leistung:
-22.96%
1J Leistung:
+1.29%
1-Tages-Spanne:
Value
$24.00
$25.05
1-Wochen-Bereich:
Value
$24.00
$27.00
52-Wochen-Spanne:
Value
$18.35
$35.00

Xoma Royalty Corp Stock (XOMA) Company Profile

Name
Firmenname
Xoma Royalty Corp
Name
Telefon
510-204-7239
Name
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Name
Mitarbeiter
13
Name
Twitter
@xomacorp
Name
Nächster Verdiensttermin
2025-03-17
Name
Neueste SEC-Einreichungen
Name
XOMA's Discussions on Twitter

Vergleichen Sie XOMA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
XOMA
Xoma Royalty Corp
24.39 298.21M 9.71M -29.96M -14.79M -3.48
Biotechnology icon
ONC
Beone Medicines Ltd Adr
251.72 25.78B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.48 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3401 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.81 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
487.86 65.13B 14.09B 4.50B 2.96B 39.28

Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-17 Eingeleitet The Benchmark Company Buy
2024-04-29 Eingeleitet Leerink Partners Outperform
2021-09-07 Herabstufung Wedbush Outperform → Neutral
2021-06-29 Eingeleitet Aegis Capital Buy
2021-01-19 Bestätigt H.C. Wainwright Buy
2018-01-18 Bestätigt H.C. Wainwright Buy
2017-10-17 Fortgesetzt H.C. Wainwright Buy
2017-09-05 Hochstufung Wedbush Neutral → Outperform
2017-06-12 Eingeleitet H.C. Wainwright Buy
2016-11-14 Herabstufung Wedbush Outperform → Neutral
2016-03-11 Bestätigt Wedbush Outperform
2015-07-23 Herabstufung Jefferies Buy → Hold
2015-07-22 Herabstufung Ladenburg Thalmann Buy → Neutral
2015-07-22 Herabstufung Piper Jaffray Overweight → Neutral
2014-10-10 Fortgesetzt ROTH Capital Buy
2014-04-29 Hochstufung MLV & Co Hold → Buy
2014-03-11 Herabstufung MLV & Co Buy → Hold
2014-03-05 Bestätigt Ladenburg Thalmann Buy
2013-10-31 Bestätigt MLV & Co Buy
2013-05-09 Bestätigt Ladenburg Thalmann Buy
2012-05-14 Eingeleitet Cowen & Co Outperform
2011-03-31 Bestätigt MLV Capital Buy
2011-03-23 Bestätigt RBC Capital Mkts Outperform
2011-01-06 Bestätigt Ladenburg Thalmann Buy
2011-01-04 Bestätigt Wedbush Outperform
Alle ansehen

Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten

pulisher
Jun 01, 2025

Wall Street Zen Upgrades XOMA (NASDAQ:XOMA) to Buy - Defense World

Jun 01, 2025
pulisher
May 31, 2025

HC Wainwright Issues Positive Outlook for XOMA Earnings - Defense World

May 31, 2025
pulisher
May 29, 2025

XOMA Co. (NASDAQ:XOMAO) Short Interest Update - Defense World

May 29, 2025
pulisher
May 29, 2025

XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World

May 29, 2025
pulisher
May 29, 2025

XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

May 29, 2025
pulisher
May 28, 2025

XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M - MSN

May 28, 2025
pulisher
May 28, 2025

XOMA stock holds Buy rating, $104 target from H.C. Wainwright - Investing.com

May 28, 2025
pulisher
May 28, 2025

XOMA stock holds Buy rating, $104 target from H.C. Wainwright By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

May 28, 2025
pulisher
May 28, 2025

XOMA Stock: HC Wainwright & Co. Reiterates Buy Rating with $104 - GuruFocus

May 28, 2025
pulisher
May 27, 2025

XOMA Purchases Future Mezagitamab Royalty Interests from BioInve - GuruFocus

May 27, 2025
pulisher
May 27, 2025

XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInvent - GuruFocus

May 27, 2025
pulisher
May 27, 2025

XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInven - GuruFocus

May 27, 2025
pulisher
May 27, 2025

XOMA Royalty Purchases Mezagitamab Royalty and Milestone - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million - Yahoo Finance

May 27, 2025
pulisher
May 25, 2025

Northern Trust Corp Has $2.40 Million Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World

May 25, 2025
pulisher
May 23, 2025

XOMA (NASDAQ:XOMAO) Stock Price Up 0.1% – Still a Buy? - Defense World

May 23, 2025
pulisher
May 22, 2025

XOMA (NASDAQ:XOMAP) Trading Up 1.5% – Still a Buy? - Defense World

May 22, 2025
pulisher
May 20, 2025

Major Shareholder Sells Massive Chunk of Xoma Stock! - TipRanks

May 20, 2025
pulisher
May 19, 2025

Leerink Partnrs Analysts Boost Earnings Estimates for XOMA - Defense World

May 19, 2025
pulisher
May 18, 2025

FY2026 Earnings Estimate for XOMA Issued By Leerink Partnrs - Defense World

May 18, 2025
pulisher
May 16, 2025

Results: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

XOMA Royalty First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

XOMA Royalty Reports Strong Q1 2025 Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

XOMA Royalty Corp Q1 2025 Earnings: EPS of $0.24, Revenue Surges to $15.9 Million, Exceeding Estimates - GuruFocus

May 14, 2025
pulisher
May 13, 2025

XOMA (XOMA) Surpasses Q1 Revenue Expectations with Strong Pipeli - GuruFocus

May 13, 2025
pulisher
May 13, 2025

XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

XOMA Royalty Corporation Q1 2025 Financial Results - TradingView

May 13, 2025
pulisher
May 13, 2025

XOMA Royalty Corp SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements - The Manila Times

May 13, 2025
pulisher
May 12, 2025

Wells Fargo & Company MN Grows Stock Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World

May 12, 2025
pulisher
May 11, 2025

Barclays PLC Acquires 1,528 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World

May 11, 2025
pulisher
May 07, 2025

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference - GlobeNewswire

May 07, 2025
pulisher
May 05, 2025

XOMA Royalty Corp expected to post a loss of 30 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Buys 7,619 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World

May 05, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Raises Stake in XOMA Co. (NASDAQ:XOMA) - Defense World

May 03, 2025
pulisher
May 01, 2025

XOMA Co. (NASDAQ:XOMAO) Sees Significant Increase in Short Interest - Defense World

May 01, 2025
pulisher
Apr 27, 2025

XOMA Co. (NASDAQ:XOMA) Shares Sold by Geode Capital Management LLC - Defense World

Apr 27, 2025
pulisher
Apr 21, 2025

Short Interest in XOMA Co. (NASDAQ:XOMAP) Drops By 15.9% - Defense World

Apr 21, 2025
pulisher
Apr 19, 2025

Benchmark Begins Coverage on XOMA (NASDAQ:XOMA) - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Benchmark Initiates Coverage of XOMA Royalty CorporationPreferred Stock (XOMAP) with Buy Recommendation - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

Benchmark Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

XOMA Co. (NASDAQ:XOMAO) Sees Large Decrease in Short Interest - Defense World

Apr 17, 2025
pulisher
Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

XOMA Royalty Corporation's (NASDAQ:XOMA) Path To Profitability - Yahoo

Apr 15, 2025
pulisher
Apr 14, 2025

XOMA completes sale of Kinnate assets for up to $270 million - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Xoma Royalty Completes Sale Of Kinnate Pipeline Assets - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

XOMA Royalty Completes Sale of Kinnate Pipeline Assets - The Manila Times

Apr 14, 2025
pulisher
Apr 12, 2025

XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber Buys 17,935 Shares - MarketBeat

Apr 12, 2025
pulisher
Apr 11, 2025

XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com - Defense World

Apr 11, 2025

Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Xoma Royalty Corp-Aktie (XOMA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Hughes Owen
Chief Executive Officer
May 20 '25
Sale
25.38
25,637
650,667
62,701
BURNS THOMAS M.
SVP, Finance & CFO
May 19 '25
Option Exercise
0.00
17,773
0
33,045
BURNS THOMAS M.
SVP, Finance & CFO
May 20 '25
Sale
25.38
10,482
266,033
22,563
BVF PARTNERS L P/IL
10% Owner
May 16 '25
Sale
27.10
392,723
10,642,793
1,267,545
Sitko Bradley
Chief Investment Officer
Apr 07 '25
Buy
24.70
2,000
49,400
5,045
LIMBER JOSEPH M
Director
Apr 03 '25
Buy
25.24
17,935
452,631
16,524
LIMBER JOSEPH M
Director
Apr 04 '25
Buy
25.40
6,822
173,293
20,000
LIMBER JOSEPH M
Director
Apr 07 '25
Buy
25.60
5,243
134,221
10,000
Sitko Bradley
Chief Investment Officer
Mar 31 '25
Buy
21.04
1,245
26,201
11,484
BURNS THOMAS M.
SVP, Finance & CFO
Apr 01 '25
Buy
25.46
1,000
25,460
2,000
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):